treprostinil / Generic mfg. - LARVOL DELTA

Prostaglandins prevent long-lasting pain in a mouse model of chronic postsurgical pain. (PubMed, Br J Anaesth) - "We show that prostaglandin agonists can produce a surprising analgesic effect. Prostaglandin receptor agonists show promise in preventing and resolving CPSP by upregulating S100A8/A9 through the PKA-STAT3 pathway in innate immune cells, suggesting a new therapeutic approach for chronic postsurgical pain."

Journal • Preclinical • Pain • S100A8

Protective effects of treprostinil and ischemic preconditioning on hepatic ischemia-reperfusion injury and biomarkers in experimental studies in rats. (PubMed, World J Gastrointest Surg) - "HIRI results in oxidative stress and cytokine overexpression, which deteriorate hepatic function and accelerates myocardial damage. Treprostinil and IP are promising strategies for preventing reperfusion-induced cellular and systemic damage."

Journal • Preclinical • Cardiovascular • Hepatology • Liver Failure • Oncology • Reperfusion Injury • Transplantation • EDN1 • IL1B • TNFA

Drug-induced headache reports: a comprehensive disproportionality and time-to-onset pharmacovigilance study using the FAERS database (2018-2024). (PubMed, Front Pain Res (Lausanne)) - "The drugs with the highest headache risk based on ROR included glecaprevir/pibrentasvir (ROR = 10.445), sofosbuvir/velpatasvir (ROR = 9.729), and eptinezumab-jjmr (ROR = 6.775). Top frequently reported drugs were apremilast, treprostinil, and adalimumab...Early-onset headaches (≤7days) were particularly associated with ofatumumab and fingolimod. Late-onset headaches (>90days) were linked to treprostinil and infliximab-dyyb. This large-scale pharmacovigilance study identifies multiple drugs and therapeutic classes with significant associations to headache as an ADR. These findings highlight the need for proactive headache monitoring, particularly during early treatment phases, and warrant further prospective investigations to understand mechanisms and preventive strategies."

Adverse events • Journal • Pain

Efficacy of 10% lidocaine gel for injection site pain associated with treprostinil in the treatment of pulmonary hypertension: a report of four cases. (PubMed, JA Clin Rep) - No abstract available

Journal • Cardiovascular • Hypertension • Pain • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

A 'call to action' in determining and estimating a minimum important difference (MID) in 6-minute walking distance (6MWD) in PH-ILD (BTS WM 2025) - P2/3 | "The trial comprises of both a treatment (Treprostinil, TRT) and placebo (PLB) arm...The SEE methodology provided a MCID of 31 m however, when an expert response was excluded based on task comprehension concerns and lack of PH experience, an MCID of 28.6 m was established. Conclusion This study has established an interim 6MWD MID for PH-ILD that ranges between 19 m to 31 m. Due to the variability of the MID for PH-ILD, this study is a 'call-to-action' for more research to be conducted."

Cardiovascular • Interstitial Lung Disease • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

Defining the antifibrotic mechanisms of treprostinil in pulmonary fibrosis (BTS WM 2025) - "Fibroblast proliferation was also inhibited in a concentration-dependent manner by Treprostinil and there were additive effects when combined with nintedanib, pirfenidone, or nerandomilast. Antifibrotic effects of Treprostinil were detected in IPF derived PCLS. Further studies are ongoing to establish the underlying mechanism as there were additive effects of Treprostinil with established antifibrotic agents which may have important clinical implications."

Cardiovascular • Fibrosis • Idiopathic Pulmonary Fibrosis • Immunology • Interstitial Lung Disease • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases • RHOA • SERPINE1 • TGFB1

The differential effects of cAMP mobilizing agents on TGF-β-induced extracellular matrix in human lung-derived fibroblasts: insights into therapeutic targets for lung fibrosis. (PubMed, Respir Res) - "The anti-fibrotic properties of treprostinil are primarily mediated by the IP receptor, acting through both Gαs-dependent and -independent pathways. Understanding the differential effects of cAMP-mobilizing pathways on HLF fibrotic signatures can provide insight into developing novel targets to manage IPF."

Journal • Fibrosis • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases • TGFB1

Treprostinil Iontophoresis in Diabetic Foot Ulcers: A Single Ascending Dose Safety Study. (PubMed, Fundam Clin Pharmacol) - "Our results suggest that iontophoresis of treprostinil is a safe procedure at 0.25 mg/mL, without systemic adverse effect, suggesting its potential as a targeted treatment for DFUs."

Journal

Enhanced Electrochemical Sensing of Treprostinil: A Novel Approach for Sensitive and Selective Detection. (PubMed, ACS Omega) - "The developed sensor demonstrated a wide linear range, low detection limit, and high reproducibility, making it a promising tool for clinical and pharmaceutical applications. This study provides a significant advancement in the electrochemical analysis of TRP, paving the way for further applications in drug monitoring and biomedical research."

Journal • Cardiovascular • Hypertension • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

Acute Hemodynamic Effects of Sotatercept in Pulmonary Arterial Hypertension (AHA 2025) - P | "Our findings provide the first indication of an acute pulmonary vasodilatory effect of sotatercept. Sotatercept may rapidly unload the RV but does not influence RV–PA coupling acutely. Clinically, sotatercept could be beneficial for immediate RV unloading in acute settings."

Late-breaking abstract • Cardiovascular • Pulmonary Arterial Hypertension • Respiratory Diseases

Case report: Successful use of sotatercept to treat pulmonary arterial hypertension in a patient with hereditary hemorrhagic telangiectasia. (PubMed, Respir Med Case Rep) - "Despite long-term treatment with epoprostenol, treprostinil, macitentan, and tadalafil, her condition progressed, leading to evaluation for lung transplantation. This is the first reported case of sotatercept use in HHT-associated PAH, highlighting its potential efficacy but also the need for careful monitoring due to increased bleeding risk. Further studies are required to establish the safety and efficacy of sotatercept in this population."

Journal • Cardiovascular • Heart Failure • Hematological Disorders • Hypertension • Otorhinolaryngology • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases • Transplantation • TGFB1

Comparing Pulmonary Arterial Hypertension Care in Urban and Rural Settings: Treatment Patterns and Risk Trajectories. (PubMed, Pulm Circ) - "However, among patients receiving triple therapy, rural patients were significantly more likely to receive inhaled treprostinil as the prostacyclin component (p = 0.03)...These findings suggest that although care delivery appeared comparable across settings, differences in treatment selection and risk trajectories emerged over time. Further investigation is needed to understand the drivers of these differences and their implications for disease management and progression."

Journal • Cardiovascular • Hypertension • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

Treprostinil Improves Renal Blood Flow and Function During Renal Ischemia-Reperfusion Injury Through IP/cAMP/PKA Signaling (KIDNEY WEEK 2025) - "Conclusion Treprostinil improves renal blood flow and kidney function early post-reperfusion via activation of IP/cAMP/PKA signaling in a clinically relevant rat model of renal IRI. These findings support the clinical investigation of treprostinil as a novel therapy to reduce renal IRI during kidney transplantation."

Acute Kidney Injury • Cardiovascular • Nephrology • Reperfusion Injury

Real-World Comparison of Patients With PH-ILD Initiating Inhaled Treprostinil Versus Patients Who Remain Untreated. (PubMed, Pulm Circ) - "Patients who initiated inhaled treprostinil had a 30% decreased risk of hospitalization compared to untreated patients (relative risk: 0.70; 95% CI: 0.59-0.83; p < 0.01). Among real-world patients with PH-ILD, treatment with inhaled treprostinil is associated with fewer all-cause hospitalizations and ICU-related hospitalizations compared to untreated patients with PH-ILD."

Journal • Real-world evidence • Cardiovascular • Hypertension • Interstitial Lung Disease • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

Repurposing of Treprostinil and Cinacalcet to Facilitate Hematopoietic Cell Transplantation (ASH 2024) - "This regimen boosts HSPC potency, improves bone marrow reconstitution, and enhances homing and engraftment properties both in vitro and in vivo.It offers two key benefits - i) enabling successful transplants with sub-threshold HSPC collections and ii) reducing the number of cells needed from donors, thereby minimizing the risks and discomfort associated with harvesting.These advantages increase the pool of willing donors and broaden the use of HCT in various clinical settings. Future studies will investigate the safety and mechanisms of this regimen, potentially transforming HCT by making it safer and more accessible for patients and donors."

Graft versus Host Disease • Immunology • Transplantation • CD34

Decluttering Complexity: A Pragmatic Framework for Simplifying Global Health Economic Models for HTA (ISPOR-EU 2025) - "The methodology is illustrated using Ferrer's inhaled treprostinil model for pulmonary hypertension associated with interstitial lung disease. We analyzed the existing combined CE and BI model to identify sources of complexity, including redundant inputs, dispersed settings across multiple sheets, and intricate data flows. This framework enables structured simplification of global health economic models without compromising robustness. It enhances usability and adaptability for global HTA needs. Further research could refine the methodology through broader use cases, and stakeholder-informed criteria."

Clinical • HEOR • Cardiovascular • Interstitial Lung Disease • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

Transitioning Between Treprostinil Formulations: Evidence and Strategies. (PubMed, Adv Ther) - "These findings underscore the importance of individualized transition strategies, informed by clinical status, patient preferences, and formulation-specific pharmacokinetics. By consolidating the current evidence, this review aims to support clinicians in optimizing transitions and maintaining continuity of treprostinil therapy.Graphical abstract available for this article."

Journal • Review • Cardiovascular • Hypertension • Interstitial Lung Disease • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

Add-on therapy with parenteral prostacyclin analogues in patients with pulmonary arterial hypertension: Insights from the COMPERA registry. (PubMed, J Heart Lung Transplant) - "Independent predictors of mortality included older age, male sex, CTD, CHD, and intermediate-high or high risk at time of PPA initiation. These findings indicate short-term clinical improvements but high subsequent mortality with add-on PPA therapy in patients with PAH, particularly in those with CTD-PAH, underscoring the need for more effective therapies."

Journal • Cardiovascular • Heart Failure • Hypertension • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases • Rheumatology

Inhaled Treprostinil Improves Cardiac Output during Exertion in Interstitial Lung Disease. (PubMed, Eur Respir J) - No abstract available

Journal • Interstitial Lung Disease • Pulmonary Disease • Respiratory Diseases

Optimization of Targeted Pulmonary Vascular Therapy for Pulmonary Hypertension Associated with Congenital Heart Disease in Children (ChiCTR) - P=N/A | N=244 | Not yet recruiting | Sponsor: Fuwai Hospital, Chinese Academy of Medical Sciences; Fuwai Hospital, Chinese Academy of Medical Sciences

New trial • Cardiovascular • Heart Failure • Hypertension • Pediatrics • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

WHEN TREATMENT TURNS TOXIC: A CAUTIONARY TALE OF POMALIDOMIDE-ASSOCIATED PULMONARY COMPLICATIONS (CHEST 2025) - "INTRODUCTION: Pomalidomide, an immunomodulatory drug much more potent than thalidomide, has significantly improved treatment outcomes for relapsed or refractory multiple myeloma (MM) but its side effect profile remains poorly understood...CASE PRESENTATION: A 79-year-old man with a history of multiple myeloma complicated by paraneoplastic pulmonary hypertension managed with three vasodilators (ambrisentan, sildenafil, and treprostinil) presented with activity-limiting shortness of breath...For multiple myeloma, he was initially treated with lenalidomide and transitioned to bortezomib...He unfortunately had relapsed disease several years later prompting treatment with bortezomib which was subsequently transitioned to a regimen consisting of daratumumab, bortezomib, dexamethasone. Shortly before evaluation for dyspnea, he was being treated with elotuzumab and pomalidomide...Pomalidomide was stopped and he was started on a tapered course of prednisone over four weeks with..."

Cardiovascular • Coronary Artery Disease • Hematological Malignancies • Hypertension • Immunology • Infectious Disease • Interstitial Lung Disease • Multiple Myeloma • Obstructive Sleep Apnea • Pneumonia • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases • Sleep Disorder

Inhaled Treprostinil (Tyvaso Nebulizer) For COPD Patients With Hypoxemia (clinicaltrials.gov) - P2 | N=10 | Recruiting | Sponsor: Bastiaan Driehuys | Phase classification: P1 ➔ P2

Phase classification • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

A NOVEL CASE OF VEGF-INHIBITOR THERAPY IN PULMONARY ARTERIAL HYPERTENSION DUE TO HEREDITARY HEMORRHAGIC TELANGIECTASIA (CHEST 2025) - "Her PAH was managed with subcutaneous treprostinil, macitentan, furosemide, and spironolactone, with significant symptomatic improvement despite ongoing severe PAH by hemodynamic measurements...Her anemia persisted despite intravenous ferumoxytol 1020 mg 1-2 times per week...This dysregulated BMP signaling pathway is the target of Sotatercept, the newest FDA-approved PAH therapy... The VEGF-inhibitor Bevacizumab has proven clinical benefits in HHT, yet there is no direct evidence supporting its use in PAH. This case demonstrates that Bevacizumab may be used safely in patients with PAH and HHT, and may improve PAH-specific metrics such as PASP, though further studies are needed to confirm its role in PAH."

Clinical • Anemia • Cardiovascular • CNS Disorders • Fatigue • Genetic Disorders • Hematological Disorders • Pulmonary Arterial Hypertension • Respiratory Diseases • ACVR2A • ACVRL1 • ALK1 • TGFB1

DE-ESCALATION OF THERAPY IN THE SETTING OF SOTATERCEPT IN PULMONARY ARTERIAL HYPERTENSION PATIENTS ON PREVIOUSLY STABLE PARENTERAL PROSTACYCLIN (CHEST 2025) - "CASE PRESENTATION: A 38-year-old female with Ehlers-Danlos and World Health Organization (WHO) group 1 PAH on triple therapy (subcutaneous treprostinil 30 ng/kg/min, macitentan, riociguat) was started on sotatercept...Six minute walk distance (6MWD) improved (460m) as did her functional class (II).A 55-year-old female with methamphetamine-associated PAH on triple therapy (epoprostenol 16.5ng/kg/min, macitentan, riociguat) was started on sotatercept...Epoprostenol was tapered off over 2 days and was transitioned selexipag... These cases highlight the importance of regular follow-up, monitoring, and dose modifications to PAH therapies. Further studies are needed to evaluate the long-term impact of sotatercept and its interactions with other PAH therapies."

Clinical • Cardiovascular • Endocrine Disorders • Infectious Disease • Nephrology • Novel Coronavirus Disease • Pneumonia • Pulmonary Arterial Hypertension • Renal Disease • Respiratory Diseases

Comparative efficacy and safety of prostacyclin therapies for pulmonary arterial hypertension: a systematic review and network meta-analysis. (PubMed, Front Med (Lausanne)) - "Hemodynamically, epoprostenol achieved optimal Pulmonary Arterial Pressure (PAP) reduction (-6.29 mmHg, 95%CI -6.99 to -5.59; P-score 0.95), while iloprost demonstrated superior Pulmonary Vascular Resistance (PVR) improvement (-342.09, 95%CI -410.30 to -273.87; P-score 1.00). Our NMA demonstrates that prostacyclin pathway therapies offer benefits in PAH management. While epoprostenol exhibits superior improvements in hemodynamics and functional capacity, treprostinil reduces mortality by 34%, and selexipag excels in preventing clinical worsening and hospitalizations."

Journal • Retrospective data • Review • Cardiovascular • Congestive Heart Failure • Heart Failure • Hypertension • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases